Alzheimer’s disease: An Updated Overview of Its Genetics
Alzheimer’s disease (AD) is a neurodegenerative disorder and represents the most common form of dementia. At present, an estimated 50% of million people worldwide suffer from some form of dementia. AD is characterized by chronic and acquired memory impairment and
Masitinib for mild-to-moderate Alzheimer’s disease: results from a randomized, placebo-controlled, phase 3, clinical trial
Alzheimer’s disease (AD) is a progressive neurodegenerative disease and the main cause of dementia, with an estimated prevalence of 50 million people worldwide that is projected to triple by 2050. Masitinib is an orally administered
Dimethyl Fumarate as Potential Treatment for Alzheimer’s Disease: Rationale and Clinical Trial Design
Alzheimer’s Disease (AD) is a debilitating disease that leads to severe cognitive impairment and functional decline.NRF-2 has been identified in modulating the effects of inflammation and oxidative stress in AD. Activation of NRF-2 leads to an increased
Histone Modifications in Alzheimer’s disease
Alzheimer’s disease is the most common neurodegenerative disorder and the most frequent cause of dementia among the elderly population. The extensive and progressive neuronal loss in the cerebral cortex of Alzheimer’s disease patients, along
Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease
Alzheimer’s disease is one of the greatest health challenges, affecting tens of millions of people worldwide. Amyloid-β(Aβ) and tau pathology are the defining pathological features of AD. Early disease prediction can be helped
Distinguishing Semantic Variant Primary Progressive Aphasia from Alzheimer’s disease
Semantic variant primary progressive aphasia (svPPA) is a unique frontotemporal degeneration that affects the semantic system in the anterior temporal lobes with progressive deterioration of semantic knowledge. It is important to